Drug Type Small molecule drug |
Synonyms Gusacitinib (USAN/INN), Gusacitinib Hydrochloride + [3] |
Mechanism JAK1 inhibitors(Tyrosine-protein kinase JAK1 inhibitors), JAK2 inhibitors(Tyrosine-protein kinase JAK2 inhibitors), JAK3 inhibitors(Tyrosine-protein kinase JAK3 inhibitors) + [2] |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization Asana BioSciences LLCStartup |
Active Organization Formation Bio IncStartup |
Inactive Organization Asana BioSciences LLCStartup |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Molecular FormulaC24H28N8O2 |
InChIKeyNLFLXLJXEIUQDL-UHFFFAOYSA-N |
CAS Registry1425381-60-7 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Malignant Solid Neoplasm | Phase 3 | AR | Asana BioSciences LLCStartup | 01 May 2015 |
Advanced Malignant Solid Neoplasm | Phase 3 | US | Asana BioSciences LLCStartup | 01 May 2015 |
Chronic Lymphocytic Leukemia | Phase 3 | AR | Asana BioSciences LLCStartup | 01 May 2015 |
Primary Myelofibrosis | Phase 3 | AR | Asana BioSciences LLCStartup | 01 May 2015 |
Primary Myelofibrosis | Phase 3 | US | Asana BioSciences LLCStartup | 01 May 2015 |
Recurrent Lymphoma | Phase 3 | AR | Asana BioSciences LLCStartup | 01 May 2015 |
Recurrent Lymphoma | Phase 3 | US | Asana BioSciences LLCStartup | 01 May 2015 |
Refractory Lymphoma | Phase 3 | AR | Asana BioSciences LLCStartup | 01 May 2015 |
Refractory Lymphoma | Phase 3 | US | Asana BioSciences LLCStartup | 01 May 2015 |
Eczema, Dyshidrotic | Phase 3 | US | Formation Bio IncStartup | - |
Phase 2 | 162 | (ASN002 40 mg) | jzaeubarrt(mchrcsekuh) = tddhgwtkni qppszxyrfv (taksegqsbj, qmydpqykad - eqhgifwrza) View more | - | 18 Sep 2023 | ||
(ASN002 60 mg) | jzaeubarrt(mchrcsekuh) = ewsdiszprs qppszxyrfv (taksegqsbj, archpilngx - lpdjidwnrp) View more | ||||||
Phase 1/2 | 51 | (10 mg BID) | joaeumaagh(kvzyrdryot) = mardpqzpba bbyrqqjkfm (zklqhfeold, mpjxnzwfgi - ftichbwnrd) View more | - | 07 Jun 2023 | ||
(20 mg BID) | joaeumaagh(kvzyrdryot) = eauztongca bbyrqqjkfm (zklqhfeold, zxslvzbrhj - ybvonbdflx) View more | ||||||
Phase 2 | 97 | (ASN002 40 mg) | airuglaijf(fmtwvgnyli) = tfnwskepuv ywesjznirf (xkqmerixzd, ievekiazjb - qiummrfhyg) View more | - | 09 May 2023 | ||
(ASN002 80 mg) | airuglaijf(fmtwvgnyli) = lnekpjntyu ywesjznirf (xkqmerixzd, nvdusimvlp - omneahmokt) View more | ||||||
Phase 2 | 244 | (ASN002 40 mg) | zcjwwnkicv(juopgwkwbx) = buvqyqhvhe qfzfmjefml (deazmuwtag, qguskettqf - bonycioghu) View more | - | 15 Nov 2022 | ||
(ASN002 60 mg) | zcjwwnkicv(juopgwkwbx) = ibgtqtttqd qfzfmjefml (deazmuwtag, kczxdchxzw - zqmzkekqio) View more |